Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-12-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on specific corporate matters related to the use of raised funds, compliance with laws and regulations, and the reappointment of the audit firm. It references legal frameworks and company bylaws but does not contain financial statements or detailed financial results. The document is a formal opinion or certification by independent directors rather than a full audit report or annual report. It is also relatively short (1240 characters), indicating it is not a comprehensive report but rather a regulatory or compliance filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such documents that do not fit other specific report types.
2021-12-10 Chinese
关于第四届董事会第二十四次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of 特一药业集团股份有限公司. It details the meeting date, attendance, and specific resolutions approved, such as the use of raised funds, appointment of an audit firm, changes to registered capital, and scheduling a shareholders meeting. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and upcoming shareholder meeting notices. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short (2120 characters), and it is a direct announcement of board meeting resolutions, not a report publication announcement or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2021-12-10 Chinese
关于签署募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for the special account storing raised funds. It details the amount of funds raised, the use of the funds, the opening of special accounts, and the supervisory responsibilities of involved parties. There are no financial statements or comprehensive financial data presented. The document is relatively short (2623 characters) and serves as a formal announcement about the management and supervision of fundraising proceeds rather than a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-12-10 Chinese
独立董事关于续聘公司财务审计机构的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the prior approval for the reappointment of the company's financial audit firm for the year 2021. It is not the audit report itself but an opinion or approval related to the audit firm appointment. The document is short (513 characters) and does not contain financial statements or audit results. It fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report. Confidence is high due to clear context and content. FY 2021
2021-12-10 Chinese
章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 特一药业集团股份有限公司 (Teyi Pharmaceutical Group Co., Ltd.) dated December 2021. It contains detailed provisions on company organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. The content is a comprehensive governance document outlining the internal rules and regulations of the company, including chapters on shareholders, board of directors, management, supervisory board, financial accounting, profit distribution, and amendments to the articles. There is no indication that this is an announcement or a summary; it is the full text of the company's articles of association. This type of document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2021-12-10 Chinese
东莞证券关于特一药业使用非公开发行部分闲置募集资金暂时补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the use of idle raised funds from a non-public stock issuance by Te Yi Pharmaceutical Group Co., Ltd. It discusses the approval process, regulatory compliance, and the intended temporary use of idle funds to supplement working capital. The document references regulatory approvals, board and independent director opinions, and audit reports related to the non-public issuance. It is not a full financial report but rather a regulatory compliance and verification statement related to capital use. The document length is about 3,050 characters, which is relatively short and focused on a specific capital use issue. This fits best under Capital/Financing Update (CAP), as it concerns the use and management of funds raised through financing activities, rather than an announcement of a report or a full audit or annual report.
2021-12-10 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.